Abstract
The coronaviral spike is the dominant viral antigen and the target of neutralizing antibodies. We show that SARS-CoV-2 spike binds biliverdin and bilirubin, the tetrapyrrole products of haem metabolism, with nanomolar affinity. Using cryo-electron microscopy and X-ray crystallography we mapped the tetrapyrrole interaction pocket to a deep cleft on the spike N-terminal domain (NTD). At physiological concentrations, biliverdin significantly dampened the reactivity of SARS-CoV-2 spike with immune sera and inhibited a subset of neutralizing antibodies. Access to the tetrapyrrole-sensitive epitope is gated by a flexible loop on the distal face of the NTD. Accompanied by profound conformational changes in the NTD, antibody binding requires relocation of the gating loop, which folds into the cleft vacated by the metabolite. Our results indicate that the virus co-opts the haem metabolite for the evasion of humoral immunity via allosteric shielding of a sensitive epitope and demonstrate the remarkable structural plasticity of the NTD.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was funded by the Francis Crick Institute (FC001061, PC), which receives its core funding from Cancer Research UK, the UK Medical Research Council, and the Wellcome Trust. It was funded also by US National Institutes of Health (grant number AI150481, PC) the Kings Together Rapid COVID-19 Call award (KJD and MHM), the Huo Family Foundation (MHM and KJD) and by the UCL Coronavirus Response Fund made possible through generous donations from UCL supporters, alumni and friends (LEM, LM). Flow cytometry was supported by a multi-user equipment grant from The Wellcome Trust to MHM and KJD (208354/Z/17/Z). LEM is supported by a Medical Research Council Career Development Award (MR/R008698/1). MJvG is a recipient of an AMC Fellowship, and RWS is a recipient of a Vici grant from the Netherlands Organization for Scientific Research (NWO). CG was supported by the MRC-KCL Doctoral Training Partnership in Biomedical Sciences (MR/N013700/1). MOM, EP and RST were supported in part by an UKRI/MRC Covid-19 grant (MC_PC_19078). EN, MJS, JH receive support from the UKRI COVID-19 research scheme. This study is part of the EDCTP2 program supported by the European Union (grant number RIA2020EF-3008 COVAB) (KJD and MHM). The views and opinions of authors expressed herein do not necessarily state or reflect those of EDCTP. This research was funded in whole, or in part, by the Wellcome Trust. For the purpose of Open Access, the author has applied a CC BY public copyright license to any author accepted manuscript version arising from this submission.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The use of these sera was approved by the CDRTB Steering Committee in accordance with the responsibility delegated by the National Research Ethics Service (South Central Ethics Committee Oxford C, NRES references 15/SC/0089 and 20/SC/0226). Additionally, serum or plasma samples were obtained from University College London Hospitals (UCLH) COVID-19 patients testing positive for SARS-CoV-2 infection by RT-PCR and sampled between March 2020 and April 2020. Patient sera were from residual samples prior to discarding, in accordance with Royal College Pathologists guidelines and the UCLH Clinical Governance for assay development and approved by the Health Research Authority (HRA, IRAS reference 284088).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The crystal structure of the NTD in complex with biliverdin and associated X-ray diffraction data are deposited with the Protein Data Bank under accession code 7B62. The cryo-EM maps and refined models of the trimeric SARS-CoV-2 spike will be released prior to publication of the peer-reviewed manuscript. Further information and requests for unique reagents should be directed to the corresponding authors.
